- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02385773
Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease
A Double Blind, Randomized, Placebo-Controlled Trial to Assess the Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double-blind, randomized control trial of the nutritional product PTM202, which is a food product based on cow milk colostrum and eggs from hens that have been immunized against human diarrheal pathogens. Children between the ages of 6 months and 3 years will be enrolled at two sites in Guatemala who present with acute diarrhea. The study will have two strata according to the severity of the diarrhea.
The study product will be administered over 3 days, and the investigators will assess the impact on diarrhea duration and severity, and then follow subjects for 4 weeks to assess the impact of the nutritional product on weight gain following the episode, because poor weight gain is a major health problem in low-income countries. The investigators will also monitor for any adverse events during the trial.
The duration of participation will be 31 days for all subjects.
A stool sample will be collected at enrollment to ascertain the etiology of the diarrhea. A second sample will be collected at the end of the study to assess changes in pathogens.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Coatepeque, Guatemala
- Clínicas del Centro de Desarrollo Humano
-
Guatemala City, Guatemala
- Hospital Roosevelt
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject's parent or legal guardian is willing and able to give informed consent for participation in the trial.
- Male or Female, aged 6 months to 35 months.
- Presenting to care for acute diarrhea of 72 hours duration or less at the time of enrollment.
- Greater than 3 liquid stools in the previous 24 hours.
- In the Investigator's opinion, is able and willing to comply with all trial requirements.
- Additional inclusion for Arm 1: in addition to above, the subject will require or have already required > 8 hours of active rehydration in hospital or ER diarrheal ward, as determined by the attending physician.
- Additional inclusion for Arm 2: in addition to above, the subject will require or have already required < 8 hours of active rehydration in hospital or ER diarrheal ward, as determined by the attending physician.
Exclusion Criteria:
- Clinical condition for which oral intake of test product or placebo is contraindicated in opinion or attending physician.
- History of hypersensitivity or adverse reaction to milk or egg products.
- Condition improving in last 24 hours per parental report.
- Mild disease severity, defined as no recommended period of observed rehydration therapy per attending physician.
- Bloody Diarrhea at presentation.
- Severe malnutrition, defined as weight-for-age Z-score < -3 from median WHO published norms.
- Major congenital defects or serious chronic illness (neurologic, pulmonary, gastrointestinal liver, renal or endocrine).
- Receipt of probiotics in 72 hours prior to enrollment or recommended treatment with probiotics by attending physician
- Any confirmed or suspected immunosuppressive or immunodeficient condition including human immunodeficiency virus infection (HIV).
- Subject who, in the opinion of the investigator or sub-investigator, is unlikely to comply with the protocol, including capability to receive follow-up telephone calls or return for final visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PTM202
|
Administration of study nutritional product once per day for 3 days starting immediately after enrollment
Other Names:
|
Placebo Comparator: Enfamil Puramino
Formal Placebo
|
Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of diarrhea
Time Frame: Subjects will be followed for the duration of the diarrheal illness, with an expected average duration of 72 hours
|
Duration in hours until subject has achieved a 12 hour period without diarrheal stools
|
Subjects will be followed for the duration of the diarrheal illness, with an expected average duration of 72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight gain after diarrhea
Time Frame: 2 weeks
|
Weight will be assessed 14 days after the day 3 rehydrated baseline weight
|
2 weeks
|
Weight gain after diarrhea
Time Frame: 4 weeks
|
Weight will be assessed 28 days after the day 3 rehydrated baseline weight
|
4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James T Gaensbauer, MD, University of Colorado, Denver
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-1372
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diarrhea
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
-
Napo Pharmaceuticals, Inc.Active, not recruitingAdult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related DiarrheaUnited States, Taiwan, Georgia, Serbia, Argentina
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Hospital San BartolomeInstituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo...Unknown
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Sana'a UniversityCompleted
-
PATHUniversity of Maryland; Center for Vaccine Development - MaliCompleted
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Augusta UniversityNRS Medical College, Kolkata, West Bengal, India; School of Tropical Medicine...Terminated
Clinical Trials on PTM202
-
PanTheryx, Inc.Completed
-
NIZO Food ResearchPanTheryx, Inc.CompletedTraveler's DiarrheaNetherlands
-
University of VirginiaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Virginia...CompletedEnvironmental Enteric DysfunctionBangladesh